Login
Israel-Hamas Conflict
Independence Day
Floods
Natural Disasters
Real Madrid
World Cup
Social Media
Artificial Intelligence
Soccer
Donald Trump
BRICS
Parade
South America
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

ICI Rechallenge With Anlotinib May Benefit Pretreated ES-SCLC

Summary by oncnursingnews.com
Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
oncnursingnews.comoncnursingnews.com

ICI Rechallenge With Anlotinib May Benefit Pretreated ES-SCLC

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

oncnursingnews.com broke the news in on Tuesday, July 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal